Article

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess Study

2025-01-13

Abstract excerpt

<title>Abstract</title> <p>Pro-angiogenic factors play a crucial role in the treatment of malignant tumors, particularly in anti-angiogenic therapies. This study evaluated vascular and lymphatic adverse events (AEs) associated with four anti-tumor angiogenesis drugs in the WHO-VigiAccess database. It also compared the adverse drug reaction (ADR) profiles of these drugs to support personalized treatment decisions...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 59a7ebbb-3616-5417-ac0f-bad394fec259
DOI: 10.21203/rs.3.rs-5762345/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess StudyDOI 10.21203/rs.3.rs-5762345/v1Read

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databasesSemantic proximity Read

Distinct Adverse Event Profiles of Eight Chemotherapeutic Agents: A FAERS Database Analysis Focusing on Peripheral NeuropathySemantic proximity Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity Read

Adverse drug reactions associated with the use of biological agentsSemantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read

Signal mining and risk analysis of the over-indications use of bevacizumabSemantic proximity Read

A disproportionate analysis of novel oral anticoagulants in the overall and pediatric populations: a pharmacovigilance study based on FDA Adverse Event Reporting System databaseSemantic proximity Read